VMAT2

Vesicular monoamine transporter 2 (VMAT2) is a protein embedded in the membrane of small storage sacs — synaptic vesicles — inside monoamine-releasing neurons. Its job is to move dopamine, serotonin, norepinephrine, epinephrine, and histamine from the fluid of the cell into those vesicles, where they are held until a signal triggers their release into the synapse.

VMAT2 is the brain-dominant form of the transporter; a related protein, VMAT1, handles similar duties in peripheral tissues. Because virtually every monoamine-active substance depends on vesicular storage at some point in its mechanism, VMAT2 sits at the centre of how stimulants, empathogens, and monoamine-depleting drugs produce their effects.

How it works · its role

VMAT2 works as an antiporter: it uses the energy stored in a proton gradient across the vesicle membrane to swap protons out and monoamines in. Protons are pumped into the vesicle by a separate enzyme, creating an acidic interior; VMAT2 then exploits that gradient, moving one monoamine molecule inside for every two protons it releases outward.

The result is concentrated monoamine storage — vesicles can hold far more neurotransmitter than the surrounding cytoplasm — ready for rapid, controlled release when the neuron fires.

Critically, this transport is reversible. Under certain conditions, including the presence of some drugs, VMAT2 can run in the opposite direction, leaking stored monoamines back out of vesicles and into the cytoplasm, where other transporters then carry them out of the cell entirely.

Relevance to substances & effects

Amphetamines are the most studied VMAT2-active class. They enter neurons and cause VMAT2 to run in reverse, flooding the cytoplasm with dopamine and norepinephrine; a second transporter then pumps that excess outward into the synapse. This is why amphetamine-driven monoamine release is far larger and more abrupt than ordinary firing — it does not wait for a nerve impulse.

MDMA acts through a similar vesicle-disrupting mechanism, contributing to the large serotonin and dopamine surge that characterises its effects.

Reserpine, an older antihypertensive and antipsychotic, blocks VMAT2 directly. Rather than reversing it, reserpine prevents monoamines from being loaded into vesicles at all, gradually depleting stores. The resulting monoamine deficit was historically associated with depressive symptoms, which helped establish the connection between monoamine signalling and mood.

Tetrabenazine, used to treat movement disorders such as Huntington's disease, works by the same depletion mechanism, selectively reducing dopamine availability in affected circuits.